Regenxbio
Develop innovative therapies to treat patients with rare or otherwise debilitating disease
Based in MD
AI Overview
With $665K in lobbying spend across 13 quarterly filings, Regenxbio is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2021 to 2024.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $180K |
| 2022 | $240K |
| 2023 | $230K |
| 2024 | $15K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Regenxbio disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Taxation, Health Issues, Pharmacy
Development of innovative therapies using gene therapy; biomedical research; Prescription drug user fee implementing legislation
Potential changes in the corporate tax rate or other provisions of interest to business (no specific bill)
Potential legislation implementing value based purchasing for pharmaceuticals (no specific bill); Possible provisions of Drug Pricing Legislation (H.R. 3, H.R. 19, S. 2543 and successor legislation) t
Inclusion of provisions affecting the reimbursement of gene therapies that may be included in any drug pricing legislation or legislation on infrastructure (no specific bills)
Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.